Rifampicin - GeneCare Research

Drug Profile

Rifampicin - GeneCare Research

Alternative Names: GK-001

Latest Information Update: 15 Mar 2016

Price : $50

At a glance

  • Originator GeneCare Research Institute
  • Class Antibacterials; Antineoplastics; Antituberculars; Hepatoprotectants; Rifamycins
  • Mechanism of Action Angiogenesis inhibitors; Oxidoreductase inhibitors; Transaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Hepatocellular carcinoma

Most Recent Events

  • 15 Mar 2016 No recent reports on development identified - Phase-II for Hepatocellular carcinoma (Prevention) in France and Spain (PO)
  • 15 Mar 2016 Rifampicin is still in phase III trials for Hepatocellular carcinoma (Prevention of recurrence in patients with chronic hepatitis) in Japan (PO)
  • 25 Feb 2014 Rifampicin - GeneCare Research is available for licensing as of 01 Jan 2011. http://www.genecare.co.jp
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top